Array ( [0] => Applebot/0.1 [1] => facebookexternalhit/1.1 [2] => LinkedInBot/1.0 [3] => meta-externalagent/1.1 [4] => Amazonbot/0.1 [5] => BLEXBot/1.0 [6] => DotBot/1.2 [7] => Qwantbot/1.0_1997801 [8] => AhrefsBot/7.0 [9] => DataForSeoBot/1.0 [10] => MatchorySearch/1.3 [11] => WRTNBot/1.0 [12] => Sogou web spider/4.0 [13] => MojeekBot/0.11 [14] => Yeti/1.1 [15] => SeznamBot/4.0 [16] => SemrushBot-SI/0.97 [17] => MistralAI-User/1.0 [18] => Qwantbot/1.0 [19] => coccocbot-web/1.0 [20] => coccocbot-image/1.0 [21] => PlagAwareBot/3.2 [22] => Barkrowler/0.9 [23] => AwarioSmartBot/1.0 [24] => PetalBot [25] => archive.org_bot [26] => Iframely/1.3.1 [27] => LogRocket-AssetCacher [28] => Slackbot 1.0 [29] => node-fetch/1.0 [30] => MJ12bot/v1.4.8 [31] => MJ12bot/v2.0.0 [32] => Timpibot/0.9 [33] => AwarioBot/1.0 [34] => MJ12bot/v2.0.1 [35] => Qwantbot/1.0_2850318 [36] => SiteAuditBot/0.97 [37] => Scrapy/2.11.2 [38] => CCBot/2.0 [39] => MJ12bot/v2.0.2 [40] => Scrapy/2.13.3 [41] => WordPress/6.8.3 [42] => MJ12bot/v2.0.4 [43] => SemrushBot/7~bl [44] => Qwairy-Bot/1.0 [45] => Embedly/0.2 [46] => GeedoProductSearch [47] => SemrushBot [48] => vkShare [49] => inkrich [50] => Discordbot/2.0 [51] => IbouBot/1.0 [52] => trafilatura/1.6.3 [53] => AnsehnBot/1.0 [54] => WP-URLDetails/6.8.3 [55] => HubSpot Crawler [56] => ShapBot/0.1.0 [57] => udu/1.6.5 [58] => aiohttp/3.13.1 [59] => l9scan/2.0 [60] => Trident/5.0 [61] => SmartBotCrawler/1.0 [62] => ) The user agent is not in the allowed list.Array ( [0] => pingbot/2.0 [1] => Googlebot/2.1 [2] => ChatGPT-User/1.0 [3] => PerplexityBot/1.0 [4] => OAI-SearchBot/1.0 [5] => GPTBot/1.2 [6] => Perplexity-User/1.0 [7] => YandexBot/3.0 [8] => YandexFavicons/1.0 [9] => AdsBot-Google-Mobile [10] => AdsBot-Google [11] => Gemini-Deep-Research [12] => DuckAssistBot/1.1 [13] => DuckDuckBot/1.1 [14] => GoogleOther [15] => YandexRenderResourcesBot/1.0 [16] => YandexImages/3.0 [17] => DuckAssistBot/1.2 [18] => Baiduspider/2.0 [19] => Baiduspider-render/2.0 [20] => bingbot/2.0 [21] => YandexUserproxy [22] => Pingdom.com_bot_version_1.4_ [23] => GPTBot/1.3 [24] => PingdomPageSpeed/1.0 [25] => YandexMobileBot/3.0 [26] => ย OAI-SearchBot/1.3 [27] => ClaudeBot/1.0 [28] => OAI-SearchBot/1.3 [29] => ) The user agent is an allowed/known agent.
Veterinary Infectious Disease Diagnostics Market Size & Forecasts 2026-2035, By Segments (Animal Type, Technology, End User), Growth Opportunities, Innovation Landscape, Regulatory Shifts, Strategic Regional Insights (U.S., Japan, China, South Korea, UK, Germany, France), and Competitive Dynamics (Zoetis, IDEXX Laboratories, Heska Corporation, Abaxis (now part of Zoetis), Biogal-Galed Labs)
Market Size and Growth Outlook
Base Year Value (2025)
USD 8.29 billion
CAGR (2026-2035)
9.2%
Forecast Year Value (2035)
USD 19.99 billion
Historical Data Period
2022-2025
Largest Region
North America
Forecast Period
2026-2035
Key Takeaways
- North America region acquired over 43.8% revenue share in 2025, driven by high pet ownership rates and favorable pet insurance coverage in the region.
- Asia Pacific region will observe over 11.04% CAGR during the forecast period, accelerated by expanding livestock populations and strengthening veterinary infrastructure.
- In 2025, the companion animals segment dominated the market share, driven by rising pet ownership and increased spending on preventive animal healthcare and diagnostic testing.
- The immunodiagnostics segment contributed the largest share to the veterinary infectious disease diagnostics market in 2025, propelled by the affordability, rapid results, and widespread adoption of immunodiagnostic tests like ELISA and lateral flow assays.
- The reference laboratories segment accounted for majority share of the market in 2025, driven by the expanding role of reference laboratories in veterinary infectious disease diagnostics due to their advanced infrastructure and high-complexity testing capacity for comprehensive pathogen detection and surveillance.
- Key companies dominating the veterinary infectious disease diagnostics market are Zoetis (USA), IDEXX Laboratories (USA), Heska Corporation (USA), Abaxis (USA), Biogal-Galed Labs (Israel), VMRD (USA), Virbac (France), Thermo Fisher Scientific (USA), BioMรฉrieux (France), Neogen Corporation (USA).
Market Growth Drivers and Industry Trends
Rising Incidence of Veterinary Infectious DiseasesThe increasing prevalence of infectious diseases in livestock and companion animals is a significant growth driver for the veterinary infectious disease diagnostics market. Factors such as intensified animal farming, global trade, and climate change have contributed to outbreaks of diseases like African swine fever and avian influenza, as reported by the World Organisation for Animal Health (WOAH). This trend elevates demand for timely, accurate diagnostics to prevent large-scale losses and zoonotic spillovers. Established companies can leverage this by advancing pathogen-specific assays and comprehensive screening services, while new entrants can focus on niche markets or emerging diseases. Given continuing disease emergence and heightened biosecurity policies, diagnostic innovation and capacity expansion remain critical, reinforcing sustained market growth.
Expansion of Veterinary Diagnostic Laboratories
The growth in veterinary diagnostic laboratoriesโa response to heightened animal health surveillance and regulatory mandatesโis fueling the veterinary infectious disease diagnostics market. Government initiatives such as those from the U.S. Department of Agriculture (USDA) have increased funding and accredited lab facilities, improving testing turnaround and geographic coverage. This infrastructure growth facilitates enhanced disease monitoring and outbreak management, enabling companies to scale their service offerings and integrate advanced technologies like molecular diagnostics. For new entrants, partnerships with expanding labs present opportunities for market entry and service diversification. As regulatory frameworks strengthen globally, expanded diagnostic infrastructure will underpin more robust disease control and market evolution.
Growing Adoption of Point-of-Care Diagnostic Solutions
The shift towards rapid, point-of-care diagnostic testing in veterinary practice is transforming the veterinary infectious disease diagnostics market. Portable and user-friendly devices enable veterinarians to perform on-site testing with immediate results, improving treatment decisions and reducing disease spread. Companies like IDEXX Laboratories have driven adoption by commercializing compact platforms that integrate diagnostics with data analytics. This trend meets increasing demand for decentralized, efficient solutions amid rising operational costs and the need for quick disease identification. Strategic opportunities lie in developing multiplex assays and connectivity features. Continued digital advancements and the push for decentralized health management underscore the enduring role of point-of-care diagnostics in this marketโs trajectory.
Unlock insights tailored to your business with our bespoke market research solutions - Click to get your customized report now!
Stringent Regulatory Approval Processes
The veterinary infectious disease diagnostics market is constrained by complex and lengthy regulatory approval processes that vary widely between regions, impeding timely product launches and cross-border scalability. Diverse requirements from agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) demand extensive clinical validation and compliance documentation, increasing operational costs and delaying market entry. This regulatory fragmentation disproportionately burdens smaller firms lacking sufficient compliance resources, while larger companies face higher overheads and time-to-market risks. For example, the FDAโs rigorous vetting of diagnostic tools has been cited by IDEXX Laboratories as a factor extending their development cycles. Moving forward, unless harmonization initiatives by bodies like the World Organisation for Animal Health (WOAH) gain momentum, these procedural intricacies will continue to slow innovation adoption and market expansion, compelling players to invest disproportionately in regulatory expertise and localized product customization.
Limited Awareness and Adoption Among Veterinary Practitioners
A significant restraint stems from limited awareness and adoption of advanced infectious disease diagnostics among veterinary practitioners, particularly in emerging markets and smaller practices. Many veterinarians rely on traditional diagnostic methods due to entrenched habits, cost constraints, or perceived complexity of novel molecular and point-of-care technologies. Reports from the American Veterinary Medical Association (AVMA) highlight that insufficient training and skepticism about new diagnostic accuracy contribute to slow uptake. This hesitancy restricts market growth by dampening demand for innovative products and reducing incentives for companies to expand outreach or invest in education programs. Established companies face barriers in scaling penetration, whereas new entrants struggle to differentiate without practitioner buy-in. Gradual improvement is anticipated as industry stakeholders, including Zoetis and IDEXX Laboratories, increase focus on practitioner education and user-friendly diagnostics; however, widespread adoption will likely remain uneven in the near term.
| Growth Driver Assessment Framework | |||||
| Growth Driver | Impact On CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising incidence of veterinary infectious diseases | 3.00% | Short term (โค 2 yrs) | North America, Europe; Spillover: Asia Pacific | Low | Fast |
| Expansion of veterinary diagnostic laboratories | 3.00% | Medium term (2โ5 yrs) | Asia Pacific, North America; Spillover: Europe | Medium | Moderate |
| Growing adoption of point-of-care diagnostic solutions | 3.20% | Long term (5+ yrs) | Europe, Asia Pacific; Spillover: North America | Low | Moderate |
Regional Demand Dynamics
Largest Region
North America
43.8% Market Share in 2025
North America dominated the veterinary infectious disease diagnostics market in 2025, accounting for 43.8% of the global share. This leadership stems primarily from high pet ownership rates combined with extensive pet insurance coverage, which drives demand for advanced diagnostic solutions. The regionโs healthcare infrastructure, supported by progressive regulatory frameworks like those enforced by the U.S. Food and Drug Administration (FDA), ensures timely approval and adoption of innovative diagnostic technologies. Additionally, leading companies such as IDEXX Laboratories have bolstered market growth by enhancing diagnostic accuracy through cutting-edge tools. Consumer preference for preventative and personalized veterinary care also contributes to this robust demand. With sustained investments in research and digital veterinary platforms, North America continues to be a critical hub for technological advancements and service delivery in infectious disease diagnostics, presenting significant opportunities for stakeholders aiming to capitalize on a mature yet evolving market landscape.
The United States anchors the North American veterinary infectious disease diagnostics market, driven by widespread pet ownership and sophisticated insurance ecosystems covering veterinary services. Regulatory agencies like the USDAโs Center for Veterinary Biologics play a pivotal role in facilitating the development and commercialization of diagnostic tests, enhancing market confidence. Major players such as Zoetis leverage these dynamics by expanding their diagnostic portfolios and engaging veterinary professionals through targeted educational programs, reflecting the countryโs strong emphasis on veterinary health. This strategic environment not only supports continuous innovation but also amplifies demand for early and accurate infectious disease detection, reinforcing the U.S. as the cornerstone of the regionโs market trajectory and a gateway for introducing novel diagnostic modalities.
Asia Pacific Market Analysis:
Asia Pacific emerged as the fastest-growing region in the veterinary infectious disease diagnostics market, registering a robust CAGR of 11.04%. This rapid growth is primarily driven by the expanding livestock populations and strengthening veterinary infrastructure across the region. Countries in Asia Pacific are witnessing heightened demand for advanced diagnostics solutions, propelled by rising consumer awareness of animal health and safety, particularly in response to zoonotic disease risks. Investments in veterinary healthcare facilities and technological modernization are also fostering the adoption of cutting-edge diagnostic tools, as seen in recent policy support from the Food and Agriculture Organization (FAO) of the United Nations encouraging sustainable livestock farming practices. The regionโs diverse agricultural landscape, coupled with increasing government collaborations and private sector innovations, positions Asia Pacific as a critical hub for market expansion in veterinary infectious disease diagnostics.
Japan plays a pivotal role in Asia Pacificโs veterinary infectious disease diagnostics market due to its robust veterinary infrastructure and stringent regulatory frameworks that promote high standards in animal health monitoring. Japanโs emphasis on precision diagnostics and biosecurity measures, supported by organizations like the Ministry of Agriculture, Forestry and Fisheries (MAFF), enhances disease control efficacy and diagnostics accuracy. Meanwhile, Chinaโs rapidly expanding livestock sector, underpinned by government initiatives such as the National Animal Disease Prevention and Control Plan, fuels significant demand for comprehensive diagnostic services. China also benefits from increasing adoption of digital and automated diagnostic technologies by leading companies like BGI Group, augmenting the regionโs growth potential. Together, Japanโs regulatory rigor and Chinaโs scalable market size reinforce Asia Pacificโs leadership and strategic opportunities within the veterinary infectious disease diagnostics market.
Europe Market Trends:
Europe held a substantial share in the veterinary infectious disease diagnostics market, driven by its well-established animal healthcare infrastructure and increasing investments in advanced diagnostic technologies. The regionโs stringent regulatory environment, as overseen by the European Medicines Agency, ensures high standards for diagnostic accuracy and safety, fueling demand for innovative solutions. Growing awareness around animal welfare and food safety has shifted consumer preferences toward early and precise detection of infectious diseases in livestock and companion animals. Additionally, Europe's focus on sustainable agriculture, coupled with digital transformation initiatives across the veterinary sector, supports the integration of rapid, point-of-care diagnostics. Recent corporate advancements, such as IDEXX Laboratories expanding its diagnostic services in key European countries, exemplify the competitive intensity fostering innovation. These dynamics collectively position Europe to capitalize on emerging opportunities by blending technological sophistication with regulatory compliance and market readiness.
Germany plays a critical role within the veterinary infectious disease diagnostics market in Europe, propelled by its robust R&D ecosystem and strong regulatory frameworks. The countryโs agricultural emphasis on both intensive and organic livestock farming drives demand for high-precision diagnostic tools to curtail disease outbreaks, as highlighted by the Federal Ministry of Food and Agricultureโs recent initiatives promoting biosecurity. Furthermore, German veterinary diagnostic companies, such as Bio-Rad Laboratories, are at the forefront of introducing cutting-edge molecular diagnostics, reflecting the countryโs innovative capabilities. This landscape encourages strategic collaborations between public institutions and private players, accelerating market penetration for novel diagnostic solutions. Germanyโs leadership in research and regulation directly supports Europeโs broader potential for delivering advanced, reliable veterinary infectious disease diagnostics underpinned by scientific excellence and operational resilience.
France represents a vital market in Europeโs veterinary infectious disease diagnostics landscape, characterized by a growing emphasis on livestock health management and disease surveillance programs. The French government, through agencies like the French Agency for Food, Environmental and Occupational Health & Safety (ANSES), reinforces disease prevention frameworks, fostering adoption of sophisticated diagnostics across the livestock sector. Consumer demand in France increasingly favors transparency and traceability, strengthening veterinary practices that utilize rapid diagnostic tools for pathogen detection. A notable example includes Vetoquinolโs recent expansion of diagnostic product lines tailored for infectious disease detection in companion animals, illustrating innovation driven by local expertise. Franceโs integration of policy support with evolving clinical practices enhances Europeโs collective capacity to address infectious disease challenges, underscoring its strategic importance within the regional veterinary diagnostics market.
| Regional Market Attractiveness & Strategic Fit Matrix | |||||
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub | Advanced | Developing | Advanced | Developing | Nascent |
| Cost-Sensitive Region | Medium | Medium | Medium | High | High |
| Regulatory Environment | Supportive | Neutral | Supportive | Neutral | Neutral |
| Demand Drivers | Strong | Strong | Moderate | Moderate | Weak |
| Development Stage | Developed | Developing | Developed | Developing | Emerging |
| Adoption Rate | High | Medium | Medium | Medium | Low |
| New Entrants / Startups | Dense | Moderate | Moderate | Sparse | Sparse |
| Macro Indicators | Strong | Strong | Stable | Stable | Weak |
No card data available for this language/report.
Segment Leadership and Growth Trends
Companion animals represented the largest share in the veterinary infectious disease diagnostics market in 2025, propelled by rising pet ownership and increased spending on preventive healthcare and diagnostic testing. This segment leads as pet owners increasingly prioritize early disease detection and wellness, driven by the humanization of pets and a growing awareness of zoonotic risks. The trend aligns with demographic shifts toward urbanization and smaller family units favoring companion animals, which has spurred demand for sophisticated diagnostics. For example, Zoetis and IDEXX Laboratories have reported expanding portfolios and service capabilities targeted at companion animal diagnostics. This segment offers strategic advantages by fostering innovation in point-of-care solutions and personalized veterinary care. Given continuous growth in pet populations and evolving consumer expectations, companion animal diagnostics are poised to remain critical for market participants focusing on enhanced disease management and diagnostic precision.
Analysis by Technology
Immunodiagnostics held the largest share in the veterinary infectious disease diagnostics market in 2025, driven by the affordability, rapid turnaround, and broad adoption of tests such as ELISA and lateral flow assays. The segmentโs leadership is rooted in its suitability for diverse diagnostic settings, from reference labs to field applications, supporting timely decision-making. Widespread use by veterinary service providers is reinforced by technological enhancements and streamlined supply chains enabling lower costs and faster delivery, as highlighted by manufacturers like Bio-rad and Thermo Fisher Scientific. Industry adoption continues to expand amid regulatory endorsements recognizing immunoassaysโ diagnostic accuracy. This creates growth opportunities for players advancing multiplex platforms and integrated digital reporting tools. Sustained investment in assay development and the need for scalable, user-friendly testing solutions ensure immunodiagnostics will retain prominence in the evolving veterinary diagnostics landscape.
Analysis by End User
Reference laboratories held largest share in the veterinary infectious disease diagnostics market in 2025, underpinned by their advanced infrastructure and capacity for high-complexity testing critical for comprehensive pathogen detection and epidemiological surveillance. Their leadership reflects growing reliance from veterinary clinics and government agencies on centralized, specialized diagnostic services amid increasing regulatory scrutiny and disease outbreak monitoring. Public health authorities like the USDA and OIE underscore the strategic importance of reference labs in controlling veterinary infectious diseases. Advancements in automation, bioinformatics, and sample logistics further reinforce their competitive advantage. The segment presents considerable strategic scope for both established laboratory chains and emerging service providers investing in high-throughput capabilities and integrated data management systems. As disease surveillance demands evolve alongside biosecurity concerns, reference laboratories will remain indispensable within the veterinary infectious disease diagnostics market ecosystem.
| Report Segmentation | |||
| Segment | Sub-Segment | Largest Segment | Fastest Growing Segment |
|---|---|---|---|
| Animal Type | Food Producing Animals, Companion Animals | ||
| Technology | Molecular Diagnostics, Immunodiagnostics, Other Technologies | ||
| End User | Veterinary Laboratories and Clinics, Reference Laboratories, Research Institutes and Universities, Point of Care / In House Testing | ||
Read our Research ApproachCompetitive Landscape and Market Positioning
Company Profile
Business Overview Financial Highlights Product Landscape SWOT Analysis Recent Developments Company Heat Map Analysis
The competitive terrain is shaped by dynamic efforts from these leaders to integrate novel diagnostic platforms and enhance test accuracy and speed. Their collaborations with biotechnology firms and investments in proprietary technologies accelerate pipeline expansion and enable seamless integration into veterinary practices. Strategic acquisitions and partnerships complement organic innovation, allowing swift response to emerging disease threats and evolving regulatory standards. This continuous enhancement solidifies market positioning and intensifies competition. Companies emphasize multiplex assays, point-of-care diagnostics, and comprehensive infectious disease panels, reflecting a commitment to drive precision medicine in veterinary care.
Strategic / Actionable Recommendations for Regional Players
In North America, leveraging strong laboratory networks to introduce integrated diagnostic services aligned with emerging molecular technologies can bolster relevance amidst fierce competition from dominant players. Forming alliances with veterinary clinics and research institutions may enhance adoption of innovative assays tailored to regional disease profiles.
Asian Pacific entities could focus on expanding collaborations with local governments and agribusiness sectors to capture growth in livestock diagnostics, supported by digital platforms and mobile testing solutions to reach underserved rural areas. Prioritizing cost-effective, rapid diagnostics for high-prevalence infections permits effective market penetration against established global players.
European stakeholders may benefit from cultivating cross-border research partnerships emphasizing sustainable animal health and antimicrobial resistance diagnostics to differentiate offerings. Combining advanced biotechnologies with regulatory expertise can facilitate the introduction of next-generation tests, addressing evolving policy and market needs across the region.
Frequently Asked Questions
How is the veterinary infectious disease diagnostics industry projected to perform over the next decade?
Veterinary Infectious Disease Diagnostics Market size is predicted to expand from USD 8.29 billion in 2025 to USD 19.99 billion by 2035, with growth underpinned by a CAGR above 9.2% between 2026 and 2035.
Which global region commands the highest percentage of the veterinary infectious disease diagnostics market?
North America region acquired over 43.8% revenue share in 2025, driven by high pet ownership rates and favorable pet insurance coverage in the region.
Which region leads in terms of year-over-year growth for the veterinary infectious disease diagnostics sector?
Asia Pacific region will observe over 11.04% CAGR during the forecast period, accelerated by expanding livestock populations and strengthening veterinary infrastructure.
Why does companion animals sub-segment dominate the animal type segment of veterinary infectious disease diagnostics sector?
In 2025, the companion animals segment dominated the market share, driven by rising pet ownership and increased spending on preventive animal healthcare and diagnostic testing.
How much is the immunodiagnostics segment expected to grow in the veterinary infectious disease diagnostics industry beyond 2025?
The immunodiagnostics segment contributed the largest share to the veterinary infectious disease diagnostics market in 2025, propelled by the affordability, rapid results, and widespread adoption of immunodiagnostic tests like ELISA and lateral flow assays.
What factors give reference laboratories segment a competitive edge in the veterinary infectious disease diagnostics sector?
The reference laboratories segment accounted for majority share of the market in 2025, driven by the expanding role of reference laboratories in veterinary infectious disease diagnostics due to their advanced infrastructure and high-complexity testing capacity for comprehensive pathogen detection and surveillance.
What are the key competitors in the veterinary infectious disease diagnostics landscape?
Key companies dominating the veterinary infectious disease diagnostics market are Zoetis (USA), IDEXX Laboratories (USA), Heska Corporation (USA), Abaxis (USA), Biogal-Galed Labs (Israel), VMRD (USA), Virbac (France), Thermo Fisher Scientific (USA), BioMรฉrieux (France), Neogen Corporation (USA).
Our Clients
Why Choose Us
Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.
Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.
Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.
Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.
Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.
Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.
Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.
Select Licence Type
